Start South Texas Accelerated Research Therapeutics

San Antonio, Texas 78229

1 studies enrolling now · 15 studies all time

What they study most

Advanced Cancer, Advanced Malignancies, Advanced Solid Tumor, Advanced or Metastatic Solid Tumors, Advanced/Metastatic Solid Tumor, Breast Cancer, Cancer, Cervical Cancer, Colorectal Cancer, Cutaneous Melanoma, Diffuse Large B Cell Lymphoma (DLBCL), Esophageal Cancer

Studies at this site

• Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer — Recruiting now
• A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors — Recruiting now
• Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas — Running, not enrolling
• A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors — Stopped early
• KZR-261 in Subjects With Advanced Solid Malignancies — Stopped early
• A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors — Completed
• A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies — Completed
• Evaluation of IGM-7354 in Adults With Relapsed and/or Refractory Cancer — Completed
• A Study of PY314 in Subjects With Advanced Solid Tumors — Stopped early
• First in Human Study of UCT-03-008 in Participants With Advanced Solid Tumors — Status unconfirmed
• Safety Study of FP-1039 To Treat Cancer — Completed
• Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies — Completed
• A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of CUDC-101 in Patients With Advanced Solid Tumors — Completed
• Companion Study for Patients Who Completed Participation in a REGN2810 (Anti-PD-1) Clinical Study — Withdrawn before enrolling
• Safety Study of CALAA-01 to Treat Solid Tumor Cancers — Stopped early